Quick Answer
Niagen Bioscience, Inc. reported Cash and Equivalents of $28.22 million for fiscal year 2021.
Niagen Bioscience, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $28.22M | +69.0% |
| 2020 | $16.70M | -11.2% |
| 2019 | $18.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $20.99M | -53.0% | -25.6% |
| December 31, 2021 | $28.22M | +69.0% | -14.8% |
| September 30, 2021 | $33.10M | +113.9% | -14.6% |
| June 30, 2021 | $38.78M | +105.3% | -13.2% |
| March 31, 2021 | $44.69M | — | +167.7% |
| December 31, 2020 | $16.70M | -11.2% | +7.9% |
| September 30, 2020 | $15.48M | — | -18.1% |
| June 30, 2020 | $18.89M | -4.4% | +0.4% |
- Niagen Bioscience, Inc. showed an increase of +69.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2021 period, Niagen Bioscience, Inc.’s cash and equivalents has grown by 50.0% (from $18.81 million to $28.22 million).
- The most recent figure is from Niagen Bioscience, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 14, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: